QS Research · Michael Burry's Scion Capital analyst template · 2006
iRhythm Holdings, Inc. (IRTC)
As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data
Report price $90.83 (close 2026-11-16); latest close $94.72 (2026-11-20), +4.3% since the report; figures re-marked at the latest close
Conclusion: PASS
Conviction low · base case none · downside -36% · upside +16%
The market is pricing iRhythm as a margin story rather than a growth story: at $90.83 the EV of $3.14B is 3.68x TTM revenue of $854.0M, while the reverse DCF needs only +0.8% revenue growth a year for ten years but an FCF margin rising from 0.9% to 20.0%. Against that, the equity still shows EBIT of -$49.0M, FCF of $7.4M and ROIC of -11.3% versus a 6.9% WACC. The call is PASS: not a value candidate at this price, rather than a verdict that the business is bad. Downside is -33.0% to $60.84 at a compressed EV/Sales of 3.13x (today 3.68x). Upside is +20.6% to $109.54 at +20% sales at today's EV/Sales of 3.68x. There is no base case: no independent multiple—peer median or own history—sets one, and a base at today's multiple is today's price by construction. The label rests on the downside and upside alone.
Key numbers
- Share price: $94.72
- Market cap: $3.18B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $854.0M
- FCF yield: 0.2%
- Price / book: 17.98x
- Earnings-quality flags (TTM): none flagged
- EV / FCF (TTM): 443.8x
- Revenue growth (latest fiscal year): +26.2%
- ROIC (TTM): -11.3%
- WACC: 6.9%
- Economic profit spread: -18.3 pts
The 15 boxes
- ✓ 1. Long-form business notes
iRhythm is a service business: it combines a 14-day patch ECG monitor with cloud analytics and Medicare-enrolled IDTF technicians to deliver long-term continuous and MCT cardiac monitoring reports to physicians and payors. The FY2020-to-FY2025 filings show a much larger platform—revenue $265.2M to $747.1M, over three million patients in the FY2020 filing versus more than twelve million patient reports in the latest, employees 1,157 to 2,400—but operating income was still negative in FY2025 and TTM to Sep 30, 2026, while operating cash flow turned positive. No segment revenue breakout is given; payor concentration is mainly third-party payors, including Medicare.
- ✓ 2. Competitive advantage
The sources show growth without a demonstrated durable moat: revenue rose from $265.2M in FY2020 to $747.1M in FY2025 and $854.0M TTM to September 2026, and gross profit rose from $194.9M to $527.2M to $617.1M, yet operating income was negative in every one of those periods (-$49.0M TTM) and net income was -$38.6M TTM. What advantage exists rests on clinical validation of its algorithms, workflow/EHR tools and contracted payor rates rather than on brand or cost position: the 10-K names competitors with 'substantially greater' resources, a fragmented field of large manufacturers and many regional service providers, and about 24% of FY2025 revenue coming from Medicare. Pricing and coverage are set administratively, and commercial payor contracts are terminable on notice, so the moat is reimbursement-dependent rather than structural. The one improving indicator is cash: operating cash flow was $80.9M in FY2025 and $55.6M TTM against capex of $48.2M TTM.
- ✓ 3. 10-Q takeaways
Q3 2026 revenue rose 14.9% to $221.6M and gross margin reached 74.2%, helped by about $3.1M of one-time tariff refunds; GAAP net loss widened to $29.9M with $49.8M of net litigation settlement expense, while adjusted EBITDA was $51.2M at a 23.1% margin. FY2026 guidance is $890M-$895M revenue and 15.5%-16.0% adjusted EBITDA margin, including about $16M of VitalConnect revenue. Unrestricted cash, cash equivalents, and marketable securities were $560.7M at Sep 30, 2026; inventory was $23.2M, and the 10-Q also discusses the June 2026 Cybersecurity Incident and VitalConnect integration risk.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.